What is the clinical evidence from this study?

Study design: Cross-Sectional. Population: Lung cancer (n=40). Intervention: High-policy Lung Cancer Prevention Score (LCPS ≥75) vs. Low-policy LCPS (<60). Primary outcome: Mortality-to-incidence ratio (MIR) (p=<0.001).

What does this research mean for the field?

The Lung Cancer Prevention Score (LCPS) provides a valid, reproducible quantitative framework that links national prevention policy strength to measurable lung cancer burden and outcomes. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to develop and validate the Lung Cancer Prevention Score (LCPS) as a framework linking prevention policies to cancer outcomes across different countries.

May 29, 2026

Global development and validation of the Lung Cancer Prevention Score (LCPS): A quantitative framework linking policy strength, incidence, and outcomes across 40 countries.

Q: What are the key findings of this study?

A Lung Cancer Prevention Score (LCPS) ≥75 was associated with a significantly lower mortality-to-incidence ratio compared to a score <60 (0.45 vs 0.65; p<0.001).

Q: What does this research mean for the field?

The Lung Cancer Prevention Score (LCPS) provides a valid, reproducible quantitative framework that links national prevention policy strength to measurable lung cancer burden and outcomes. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

The study aims to develop and validate the Lung Cancer Prevention Score (LCPS) as a framework linking prevention policies to cancer outcomes across different countries.

Key Result

A Lung Cancer Prevention Score (LCPS) ≥75 was associated with a significantly lower mortality-to-incidence ratio compared to a score <60 (0.45 vs 0.65; p<0.001).

Key Points

The study aims to develop and validate the Lung Cancer Prevention Score (LCPS) as a framework linking prevention policies to cancer outcomes across different countries.
Created two LCPS models: Policy LCPS based on 12 weighted domains and Data-Driven LCPS using various health and economic metrics.
Utilized data from GLOBOCAN 2022, WHO GTCR 2023, World Bank, and UNDP HDR 2023 covering 40 countries.
Analyses included correlation, regression, Bland–Altman agreement, and ROC AUC for the mortality-to-incidence ratio.
Policy LCPS and Data-Driven LCPS moderately correlated (r = 0.31; 95% CI –0.04–0.60).
High-policy countries (LCPS ≥75) had 17% smoking prevalence and a mortality-to-incidence ratio (MIR) of 0.45, significantly lower than lower-policy countries (LCPS <60; smoking 27%, MIR 0.65; p <0.001).
Each 10-point increase in Data-Driven LCPS predicted 2.4 fewer lung cancer cases per 100,000 (β = –0.24 ± 0.07; p = 0.002).

Study Design

Type

Cross-Sectional (n=40)

Multicenter

Yes

Structured PICO

Population

40 countries (G20 + 20 others) with data from GLOBOCAN 2022, WHO GTCR 2023, World Bank, and UNDP HDR 2023

Intervention

Lung Cancer Prevention Score (LCPS) evaluation (Policy and Data-Driven models)

Outcome

Correlation between LCPS and age-standardized incidence (ASIR), mortality-to-incidence ratio (MIR), and smoking prevalence

The Lung Cancer Prevention Score provides a validated framework connecting prevention policy to measurable cancer burden across countries.

Main Result

Absolute Event Rate: 0.45% vs 0.65%

p-value: p=<0.001

Abstract

10518 Background: Lung cancer is the leading cause of cancer worldwide. Despite advances in tobacco control, national prevention efforts remain fragmented. We developed and validated the Lung Cancer Prevention Score (LCPS), a 0–100 composite linking prevention policy strength with real-world outcomes for global benchmarking and equity tracking. Methods: Two LCPS models were created. Policy LCPS quantified 12 weighted domains: smoke-free laws, TAPS bans, ≥50% pictorial warnings, ≥75% excise tax, plain packaging, legal-age limits, e-cigarette control, LDCT screening, asbestos ban, radon plan, clean-cooking access, and occupational carcinogen controls. Data-Driven LCPS combined age-standardized incidence (ASIR), mortality (ASMR), mortality-to-incidence ratio (MIR), smoking prevalence, GDP, health expenditure, and HDI (normalized 0–1; higher = stronger prevention). Data from GLOBOCAN 2022, WHO GTCR 2023, World Bank, and UNDP HDR 2023 covered 40 countries (G20 + 20 others). Analyses included correlation, regression (adjusted for GDP, HDI), Bland–Altman agreement, and ROC AUC for MIR ≤0.60. Results: Among 32 complete datasets, Policy and Data-Driven LCPS correlated moderately (r = 0.31; 95% CI –0.04–0.60). Discrimination of favorable outcomes (MIR ≤0.60) showed AUC 0.68 vs 0.77. High-policy countries (≥75) had lower smoking (17%) and MIR (0.45) than those 90 % P 1 Yes = 1 Occ carcinogen ctrl P 1.5 Yes = 1 ASIR D 1 Lower = better (1–scaled ASIR) ASMR D 1 Lower = better (1–scaled ASMR) MIR D 1 Lower = better (1–scaled MIR) Smoking prev D 1</ja

Bookmark